Recent target therapies for kidney cancer:A review of articles from ۲۰۱۸ until now

Background: Renal cell carcinoma, which is the most commontype of kidney cancer among adults, is the sixth leading causeof cancer-related death. Personalization of cancer diagnosis andtreatment is advancing rapidly due to advances in the HumanGenome Project. Target therapy based on targeting enzymes,receptors and interference in intracellular processes causes optimaland even personalized treatment. Until ۲۰۰۵, cytokinetherapies were the most widely used medical strategies to combatthis disease. During ۲۰۱۷, articles focused on kinase andimmune checkpoint inhibitors and their broad therapeutic application.Materials and Methods: We conducted search in ۳ databases;pubmed, scopus and Web of Science with the related terminologyof kidney, cancer and target-therapy. In this review, we investigated۷۵۹ relevant articles from ۲۰۱۸ up-to-now to referto the novel target therapies for kidney cancer. We classifiedthe kidney cancer types such as papillary renal cell carcinoma,clear cell renal cell carcinoma and metastatic carcinoma andcorrelated each type to proper target therapies. Furthermore, wementioned artificial intelligence-based target discoveries. In theend, we referred to the first line and combined treatment strategiesof target therapies.Results: Overall, in studies after ۲۰۱۸, various target therapieshave been proposed for different phases of disease progression,even for metastasis to other organs, distinct immune pathways are considered for therapy. Among target therapy throughgenes, T-cell proliferation-related genes have gained the mostimportance for in kidney cancer. The VEGF receptor tyrosinekinases constitute a large volume of studies in recent years. Immunecheckpoint inhibitors are located in the center of clinicaldiscussions for making decisions towards their sequentialadministration.Conclusion: Phagocytosis checkpoints are considered asemerging therapeutics for renal carcinoma which we suggest toget studied more. Targeting metabolic pathways as therapeuticopportunity, should gain more attention in kidney cancer.

کلیدواژه ها:

kidney cancer ، target-therapy ، renal cell carcinoma ، papillary renal cell carcinoma ، artificial intelligence